Core Viewpoint - The announcement details the progress of a significant transaction involving the change of control, issuance of shares for asset acquisition, and fundraising by Guilin Rhine Biotechnology Co., Ltd. [2][3] Group 1: Change of Control - The original controlling shareholder, Mr. Qin Benjun, signed agreements to transfer 60 million shares (8.09% of total shares) to Guangzhou Defu Nutrition Investment Partnership, relinquishing voting rights for 189,141,310 shares (25.50% of total shares) while retaining voting rights for 22,248,282 shares (3.00% of total shares) [3] - Following the completion of the share transfer and board restructuring, Guangzhou Defu Nutrition will become the controlling shareholder, with Ms. Hou Ming and Mr. Li Zhenfu as the joint actual controllers [3] Group 2: Issuance of Shares for Asset Acquisition - The company plans to issue shares to Defu Jinkangpu Holdings and Xiamen Defu Jinkangpu Investment Partnership to acquire 80% of Beijing Jinkangpu Food Technology Co., Ltd. [4] - Additionally, shares will be issued to Guangzhou Defu Nutrition to raise funds for purchasing a 15.50% stake from individual shareholders Li Yang and Song Jun, covering intermediary fees, transaction taxes, and supplementing working capital [4] Group 3: Progress of the Transaction - As of the announcement date, the parties involved are actively progressing with the share transfer agreement, including payment of the transfer price, in accordance with the agreement [7] - The company and related parties are steadily advancing the audit, evaluation, and due diligence processes related to the transaction, with plans to convene the board again for further approvals once these tasks are completed [8]

桂林莱茵生物科技股份有限公司 证券代码：002166 证券简称：莱茵生物 公告编号：2026-002 桂林莱茵生物科技股份有限公司 关于公司控制权变更、发行股份购买资产并募集配套资金 暨关联交易事项的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、桂林莱茵生物科技股份有限公司（以下简称"公司"）于2025年12月24 日披露了《关于控股股东签署<控制权变更框架协议><股份转让协议><表决权放 弃协议><不谋求控制权承诺函>及公司签署<发行股份购买资产协议><附条件生 效的股份认购协议><股权转让协议>暨控制权拟发生变更的提示性公告》（公告 编号：2025-076）、《桂林莱茵生物科技股份有限公司发行股份购买资产并募集 配套资金暨关联交易预案》（以下简称"《交易预案》"）及其摘要，在上述披 露文件中对本次控制权变更、发行股份购买资产并募集配套资金事项（以下统称 "本次交易"）所涉及的有关风险因素及尚需履行的审批程序进行了详细说明， 敬请广大投资者注意投资风险。 2、自本次交易披露以来，公司及相关各方积极推进本次交易所涉及的股份 转让协议 ...

Core Viewpoint - The announcement by Rhine Biotech indicates a significant change in ownership structure, with the original controlling shareholder planning to transfer a substantial portion of shares and voting rights, while the company aims to acquire a majority stake in Beijing Jinkangpu [1] Group 1: Share Transfer and Voting Rights - The original controlling shareholder, Qin Benjun, intends to transfer 60 million shares, representing 8.09% of the total share capital [1] - Qin Benjun will also relinquish voting rights for 189 million shares, which accounts for 25.50% of the total share capital [1] Group 2: Acquisition Plans - The company plans to issue shares to acquire 80% of Beijing Jinkangpu's equity and raise matching funds for this transaction [1] - The stock of the company will be suspended from trading starting December 10, 2025, and is set to resume trading on December 24, 2025 [1] Group 3: Transaction Status - As of the announcement date, the share transfer, auditing, and evaluation processes are progressing smoothly, but the transaction is subject to multiple approvals, indicating some uncertainty [1]

桂林莱茵生物科技股份有限公司 证券代码：002166 证券简称：莱茵生物 公告编号：2026-001 桂林莱茵生物科技股份有限公司 关于股东部分股份质押延期购回的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 桂林莱茵生物科技股份有限公司（以下简称"公司"）董事会近日接到大股 东秦本军先生的通知，获悉秦本军先生将其质押给国海证券股份有限公司（以下 简称"国海证券"）的股份办理了延期购回业务，现将具体情况公告如下： 注：表中数值若出现总数与各分项数值之和尾数不符，均为四舍五入原因所致（下同）。 | | | | | | | 已质押股份情况 | | 未质押股份情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 累计被质 | 合计占 | 占公司 | 已 质 押 股 | 占已 | 未质押股 | 占未 | | 股东 | 持股数量 | 持股比 | 押股份数 | 其所持 | 总股本 | 份 限 售 和 | 质押 | 份限售和 | 质押 | | 名称 | （万股） | 例 ...

Group 1 - The core viewpoint of the news is that 莱茵生物 (Laiyin Bio) has experienced a decline in stock price and significant net outflow of funds, despite a year-to-date increase in stock price [1] - As of January 14, 莱茵生物's stock price was 9.03 yuan per share, with a total market capitalization of 6.697 billion yuan [1] - The company has seen a year-to-date stock price increase of 6.86%, with a 7.12% increase over the last five trading days [1] Group 2 - For the period from January to September 2025, 莱茵生物 reported revenue of 1.272 billion yuan, representing a year-on-year growth of 8.73% [2] - The net profit attributable to shareholders for the same period was 70.3953 million yuan, which is a decrease of 30.73% year-on-year [2] - The number of shareholders as of September 30 was 46,000, a decrease of 1.66% from the previous period [2] Group 3 - Since its A-share listing, 莱茵生物 has distributed a total of 431 million yuan in dividends, with 294 million yuan distributed over the last three years [3]

Core Viewpoint - The company, Rhein Biotech, focuses on the production and operation of natural health products, emphasizing the research and production of plant functional ingredients, with a specific mention of its product, orotic acid, which is a raw material for the antiviral drug Oseltamivir [2] Group 1 - The company's sales of orotic acid currently represent a small proportion of its overall revenue [2] - The company's facility in Indiana, USA, is dedicated to the production of natural sweeteners and certain functional ingredients, with normal operations reported for its overseas business [2]

Group 1 - The core point of the announcement is that the major shareholder, Mr. Qin Benjun, has completed the procedures for the partial release and re-pledging of his shares in the company [1] - Mr. Qin plans to transfer 60 million shares, representing 8.09% of the company's total share capital, to Guangzhou Defu Nutrition Investment Partnership through a share transfer agreement [2] - The pledged shares are not intended for new financing or to meet the company's operational needs [3] Group 2 - As of the announcement date, Mr. Qin's total pledged shares and their respective proportions are detailed, indicating no risk of forced liquidation [3] - The company will continue to monitor changes in the shareholder's equity and potential disposal risks, ensuring timely disclosure obligations are met [3]

证券代码：002166 证券简称：莱茵生物 公告编号：2025-079 桂林莱茵生物科技股份有限公司 关于股东部分股份解除质押及再质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 桂林莱茵生物科技股份有限公司（以下简称"公司"）董事会近日接到大股 东秦本军先生的通知，获悉秦本军先生将其所持有的部分公司股份办理了解除质 押及再质押手续，现将具体情况公告如下： 注：表中数值若出现总数与各分项数值之和尾数不符，均为四舍五入原因所致（下同）。 | 二、股东本次股份质押的基本情况 | | --- | 桂林莱茵生物科技股份有限公司 | | | | | | | | 已质押股份情况 | | 未质押股份情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 本次质押 | 本次质押 | 合计占 | 占公司 | 已 质 押 股 | | 未质押股 | | | 股东 | 持股数量 | 持股比 | 前质押股 | 后质押股 | 其所持 | 总股本 | 份 限 售 和 | ...

Group 1 - The company announced that major shareholder Qin Benjun has notified the board about the release and re-pledging of part of his shares [1] - As of the announcement date, Qin Benjun has pledged a total of approximately 173 million shares, accounting for 23.29% of the company's total share capital [1] Group 2 - The automotive market is experiencing a surge in sales, with BMW's base price significantly reduced from the original guidance of 349,900 yuan to 225,000 yuan, alongside various subsidies for purchase taxes from multiple car manufacturers [1]

Group 1 - The core viewpoint of the news is that 莱茵生物 (Laiyin Bio) has experienced a stock price increase of 2.01% this year, despite a recent decline of 8.59% over the last five trading days [2] - As of January 5, the stock price is reported at 8.62 yuan per share, with a total market capitalization of 6.393 billion yuan [1] - The company primarily engages in the production and operation of natural health products, focusing on the extraction of functional plant components, with 98.05% of its revenue coming from plant extraction products [2] Group 2 - For the period from January to September 2025, 莱茵生物 achieved a revenue of 1.272 billion yuan, reflecting a year-on-year growth of 8.73%, while the net profit attributable to shareholders decreased by 30.73% to 70.3953 million yuan [2] - The company has distributed a total of 431 million yuan in dividends since its A-share listing, with 294 million yuan distributed over the past three years [3] - The number of shareholders as of September 30 is reported at 46,000, a decrease of 1.66% from the previous period, while the average circulating shares per person increased by 31.16% to 16,011 shares [2]